{"name":"Axoltis Pharma","slug":"axoltis-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPTGxDNExNZVgwLUtLQ2lWUER4Q1g5c0dsVVJfTlRKVnZqVHRxcmxXb0xiVFpHeG1kRnEtSGkxSDNzMk1LY0NhVkNpZ0t3aEU1S1Y1OE10ZXB5UVhlSEJDcE9CRTNvV210TG9vWFJPcFBrRmQ4OGRDd3g3VXhwajF0UjNSTklTMUx2UXFNZzhMai1tSnNsTG5KRg?oc=5","date":"2025-12-08","type":"pipeline","source":"BioXconomy","summary":"Axoltis secures $21m to tackle neurodegenerative disease - BioXconomy","headline":"Axoltis secures $21m to tackle neurodegenerative disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9HUG16Wl92REtpd3JMVC1JUGo5UzdkM1dRRnlUaVNZVzJLQllWeS0xQWpSZHdUclZsaHdyaUdoM1EtS242bHo1VlhxaUxXRkt3b0NxdVdjNVBEV0g5VzJkVTNVONIBaEFVX3lxTE0weVVoSHEteDMyRXRlcWZQT0gtcGFhczNQX1RQMlB0amxSU0pvbWQtVEdXRjVCTWtRcThxMnJEZ1VNczh2OFFNZ0hmVVc1MXlmdTY2eXU0bDVmVndrQ2pvRkpHMzBNUkdn?oc=5","date":"2025-12-03","type":"trial","source":"Pulse 2.0","summary":"Axoltis Pharma: €18 Million Closed To Advance Phase 2 ALS Candidate NX210c - Pulse 2.0","headline":"Axoltis Pharma: €18 Million Closed To Advance Phase 2 ALS Candidate NX210c - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBwRnVjazRMV25WalhFcDFWMlpYWmlIcmo2VjI3THJGaUR0Q2MwZlk2eHBGbGcyQ2tESWFkV3ZCenB0TkxhNzA2NVNTVXNnSWtFSVhNeEs2N0F3UQ?oc=5","date":"2025-12-02","type":"pipeline","source":"The Pharma Letter","summary":"Axoltis Pharma - The Pharma Letter","headline":"Axoltis Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQeE53a2VMVzltYWZHZTl6R080cjZsMTV6b2x6c0NYSnFOUkVyM3o2c2k3Z1ZodEtZRzdrREhlWHg2cmRLNTl5aVBpSnNPVjhKdnc4Yms4eWJmYjVNa3hiRW9kdUk4ODIwYnE0OUYtdGhFY25nZ21sSkJTLVh1b2VkdTNsMEhmMGpHYS1FYXBoYUtndGo5WDVZQm91Zmp2Mnh4cGF6aWlwUEhKUlJuSzRVY3dxTjVjNERQQVU4TlpkTUNoR0ZTZlRTc2UxTFRmdXJBWmJjZw?oc=5","date":"2025-12-02","type":"pipeline","source":"EU-Startups","summary":"New approaches to ALS, Alzheimer’s and Parkinson’s receive support as Axoltis Pharma secures €18 million - EU-Startups","headline":"New approaches to ALS, Alzheimer’s and Parkinson’s receive support as Axoltis Pharma secures €18 million - EU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQcGRYbTVGR1dEY3p1bWh6Y1laODBmNnVfelRXdkxCeHhZc05YZ0dNemhlTHVHZy0ySjlQbmxkYnR0dVplam5MbHJ3OExUMUxmcEVJYlJoMFE1Ujgxb0dySDk3TDR4QVhlOC1tSnJDMEZzckRfdk44TVBDWFdaLV9RSWQxTjBLeXBHQVg0?oc=5","date":"2025-12-02","type":"pipeline","source":"FinSMEs","summary":"Axoltis Pharma Raises €18M in Series A Funding - FinSMEs","headline":"Axoltis Pharma Raises €18M in Series A Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQaXJQVVFHZUdhSjlFNHRuQ3FzaTNXblhqQTQ2V2tMczdkRVpsQmV6NlBOcXg3SFVNSU1MbzR2NUJZU1FWWDYxN2JWdE5Cb3VDRTZ6MEdtc3NKaHpWaWZmWkU2TS1PQlBmalU4dGoyZXBlZFZFRy1sMWhDMlRFZlpZajFIOEdGVmFZOVlv?oc=5","date":"2025-12-02","type":"pipeline","source":"The Pharma Letter","summary":"Axoltis Pharma raises 18 million euros - The Pharma Letter","headline":"Axoltis Pharma raises 18 million euros","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNMldGejdzcUFfTzMwdFRaVW0welQzQ1JhOUxDMFp2My1tdFZCNHVFRDcyZlBrdUpDTVMxaUdURGs5dE1kYmk3MUpPRXloQjlhY0U4WWFFQmhzb212UTd1bEphbFpTMF9DMEpsU3pveFQzWWNjWWE0NnJibTItam5OMVcwR2haWHhiaXBJMTA1NVNqMTM0LTlhUFVUUV9GdzF0eUY3Mlpn?oc=5","date":"2025-12-02","type":"trial","source":"Endpoints News","summary":"Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drug - Endpoints News","headline":"Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOVFFDaERNNXZINFRUZ3pfaXh6VWdOVGNST1lrT2VjdFY0MmFzWFE2MHVsLUFOcDZFeERHcHVmeS1oZGhEUGxkTDBVa3FiV0FESGpTMEdIdW52UzU5VmFnUjNrZDBLN0hKNm1SSklKdkxjcnBhZFNuNHVhMThuUUdTSWJFT003Ymx4Ry1LWmQwa1FsTTNWR1NvWEl3UQ?oc=5","date":"2024-01-03","type":"trial","source":"ALS News Today","summary":"ALS candidate NX210c is safe, well tolerated in healthy volunteer study - ALS News Today","headline":"ALS candidate NX210c is safe, well tolerated in healthy volunteer study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNTF9sem5xLVdtVlg1N3lMSUhNbUQxVGcwcnA2a0hONHdWT1hCMHM4amZndFJPeFpSR1YxbmZPTUhGZURLNUJMQUcwMEtKekxLa2UyZUZEbkx3NHdsYUcybWtCRlpWcjRtRkJ1cHlxdmlMNm1yVU9FQV9FUzFlZ2JoRjZLVmcteUlfVUFfbW5WM2pMNnAzWFZmaEd1Zk4tU2NMNGtjOFpJOHZHc0xYajFOVEFTTTFkRzdobzhCVll0WHhjbERlWXBMTXZHY1ZxOWJRenF3X2Q5MUhVeVdmcWJCTENjZU9RMU1UREJUVTNUQmpNQms?oc=5","date":"2023-07-27","type":"trial","source":"PR Newswire","summary":"InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders - PR Newswire","headline":"InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}